The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as an initial treatment in unselected patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the China cohort of the phase 3 TALAPRO-2 trial.
 
Xiaojie Bian
No Relationships to Disclose
 
Hao Zeng
No Relationships to Disclose
 
HongQian Guo
No Relationships to Disclose
 
Nianzeng Xing
No Relationships to Disclose
 
Yong Yang
No Relationships to Disclose
 
Boxin Xue
No Relationships to Disclose
 
Xiaoping Zhang
No Relationships to Disclose
 
Wenjun Xiao
No Relationships to Disclose
 
Junhui Jiang
No Relationships to Disclose
 
Ting Sun
No Relationships to Disclose
 
Wei Chen
No Relationships to Disclose
 
Yong Wang
No Relationships to Disclose
 
Ben Wan
No Relationships to Disclose
 
Dalin He
No Relationships to Disclose
 
Qi Zhang
No Relationships to Disclose
 
Hong Luo
No Relationships to Disclose
 
Xiaolin Wang
No Relationships to Disclose
 
Jianming Guo
No Relationships to Disclose
 
Huadong Zhao
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Dingwei Ye
No Relationships to Disclose